Novo Nordisk once weekly insulin fails to get thumbs up from majority of FDA advisors

 FDA advisory panel expresses concerns about the risks of Novo Nordisk's once-weekly insulin icodec outweighing the benefits.

https://seekingalpha.com/news/4110352-novo-nordisk-once-weekly-insulin-fails-get-thumbs-up-majority-fda-advisors